中文摘要：

目的：探讨吸入型糖皮质激素（ICS）治疗儿童咳嗽变异性哮喘（CVA）的临床疗效，同时进行药物经济学评价，为儿童 CVA 的临床合理、经济用药提供参考。方法将2013年3月至2014年5月就诊的128例 CVA 患儿按照随机数字表法分成 A、B、C 三组。在给予支气管扩张剂、平喘及祛痰药的基础上，A、B、C三组患儿分别给予布地奈德气雾剂吸入（200～800μg／d，分2次使用）、丙酸氟替卡松气雾剂吸入（50～100μg／次，2次／d）、丙酸倍氯米松气雾剂吸入（50～100μg／次，3次／d），治疗12周后评价临床疗效，并采用成本-效果分析法进行药物经济学研究。结果 A、B、C 三组的临床总有效率分别90．0％、93．4％、90．7％，差异有统计学意义（χ2＝25．215、22．878、21．336，均 P ＞0．05），A、B、C 三组的人均成本分别是498．68元、671．20元、541．14元，A 组具有最低的成本-效果比（C ／E ＝5．54）。结论布地奈德气雾剂治疗儿童 CVA 具有较好的经济性。

英文摘要：

Objective To discuss the clinical curative effect and pharmacoeconomics of inhaled glucocortico-steroids（ICS）in the treatment of children with cough variant asthma（CVA）,in order to provide the reference for reasonable and economic drug -use of clinic treating children with CVA.Methods 128 children with CVA were divided into A,B,C three groups according to random number table method in our hospital from March 2013 to May 2014.The children with CVA of A,B,C groups were respectively given budesonide aerosol（200 -800μg/day,twice per day）,fluticasone propionate aerosol（50 -100μg/time,twice per day）,beclometasone dipropionate aerosol（50 -100μg/time,three times per day）on the basis of bronchodilator,smooth wheezing and expectorant.The clinical effica-cy and cost -effectiveness was evaluated after 12 weeks of treatment.Results The clinical total effective rates of A, B,C group were 90.0%,93.4%,90.7% respectively,and there were no statistically significant difference（χ2 =25.215,22.878,21.336,all P 〉0.05 ）.The per capita cost of A,B,C group were 498.68yuan,671.20yuan, 541.14yuan respectively,and A group had the lowest cost -effectiveness ratio（C /E =5.54）.Conclusion Budes-onide aerosol has better economy in treating of children with CVA.